Efinopegdutide
| Clinical data | |
|---|---|
| Other names | MK-6024 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Efinopegdutide (MK-6024) is a dual agonist of the glucagon and GLP-1 receptors. It is being developed by Merck for non-alcoholic fatty liver disease. It was also developed for type 2 diabetes and obesity but these indications were discontinued.[1][2][3][4]
References
[edit]- ^ Romero-Gómez, Manuel; Lawitz, Eric; Shankar, R. Ravi; Chaudhri, Eirum; Liu, Jie; Lam, Raymond L.H.; Kaufman, Keith D.; Engel, Samuel S.; Bruzone, Santiago Oscar; Coronel, Maria Jimena; Gruz, Fernando M.; MacKinnon, Ignacio; George, Jacob; Muller, Kate; Lee, Samuel S. (2023-06-22). "A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease". Journal of Hepatology. 79 (4): 888–897. doi:10.1016/j.jhep.2023.05.013. hdl:10261/349752. ISSN 0168-8278.
- ^ Novikoff, Aaron; Müller, Timo D. (July 2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165: 171003. doi:10.1016/j.peptides.2023.171003. PMC 10265134. PMID 36997003.
- ^ Zhihong, Yao; Chen, Wang; Qianqian, Zhu; Lidan, Sun; Qiang, Zhou; Jing, Han; Wenxi, Wang; Bhawal, Ruchika (April 2023). "Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity". Peptides. 162: 170955. doi:10.1016/j.peptides.2023.170955. PMID 36669563. S2CID 255969171.
- ^ Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240. PMID 34176426. S2CID 235661514.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |